BACKGROUND: Specific peptide ligands to cell surface receptors have been extensively used in tumor research and clinical applications.
Phage display technology is a powerful tool for the isolation of cell-specific peptide ligands. To screen and identify novel markers for renal cell carcinoma, we evaluated a peptide that had been identified by phage display technology.
METHODS: A renal carcinoma cell line A498 and a normal renal cell line HK-2 were used to carry out subtractive screening in vitro with a phage display peptide library. After three rounds of panning, there was an obvious enrichment for the phages specifically binding to the A498 cells, and the output/input ratio of phages increased about 100 fold. A group of peptides capable of binding specifically to the renal carcinoma cells were obtained, and the affinity of these peptides to the targeting cells and tissues was studied.
RESULTS: Through a cell-based ELISA, immunocytochemical staining, immunohistochemical staining, and immunofluorescence, the Phage ZT-2 and synthetic peptide ZT-2 were shown to specifically bind to the tumor cell surfaces of A498 and incision specimens, but not to normal renal tissue samples.
CONCLUSION: A peptide ZT-2, which binds specifically to the renal carcinoma cell line A498 was selected from phage display peptide libraries. Therefore, it provides a potential tool for early diagnosis of renal carcinoma or targeted drug delivery in chemotherapy.
Written by:
VTu X, Zhuang J, Wang W, Zhao L, Zhao L, Zhao J, Deng C, Qiu S, Zhang Y. Are you the author?
Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, Guangdong, PR China.
Reference: J Exp Clin Cancer Res. 2011 Nov 10;30:105.
PubMed Abstract
PMID: 22071019
UroToday.com Investigational Urology Section
